CLRB - Cellectar Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.30
0.00 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.30
Open2.24
Bid1.50 x 1000
Ask2.36 x 1100
Day's Range2.24 - 2.34
52 Week Range2.03 - 15.90
Volume18,118
Avg. Volume244,981
Market Cap8.269M
Beta (3Y Monthly)0.58
PE Ratio (TTM)N/A
EPS (TTM)-9.51
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.40
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update

    Cellectar Biosciences, Inc. (CLRB) (“Cellectar” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today reported financial results for the three and nine months ended September 30, 2018 and provided a business update. Announced that the U.S. Food and Drug Administration has granted an exemption to the Import Alert for CLR 131 in all hematology indications, effective immediately.  The company continues to work with the appropriate division of the FDA to obtain an exemption for its pediatric program, evaluating CLR 131 in multiple childhood cancers with significant unmet medical need.

  • GlobeNewswire6 days ago

    Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted an exemption to the Import Alert placed on the Centre for Probe Development and Commercialization (CPDC), the sole supplier of the CLR 131. The exemption for CLR 131 is effective immediately for all hematology studies and, in response, Cellectar is preparing to dose patients in the second fractionated dose cohort of the Phase 1 relapsed refractory (R/R) multiple myeloma study and the Phase 2 study for R/R hematologic malignancies.

  • GlobeNewswire2 months ago

    Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma

    MADISON, Wis., Oct. 02, 2018 -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of.

  • GlobeNewswire2 months ago

    Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference

    MADISON, Wis., Sept. 27, 2018-- Cellectar Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences

    NEW YORK, NY / ACCESSWIRE / September 27, 2018 / U.S. markets fell sharply Wednesday after the Federal Reserve raised interest rates and indicated another increase would be coming in December. The Dow ...

  • GlobeNewswire2 months ago

    Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of pediatric osteosarcoma, a rare pediatric cancer. CLR 131 also received Rare Pediatric Disease Designation for osteosarcoma, as announced by the company on September 17, 2018.

  • GlobeNewswire2 months ago

    Cellectar Biosciences Provides an Update on the FDA Import Alert

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has initiated direct talks with the company concerning a possible exemption for CLR 131 from the Import Alert placed on the Centre for Probe Development and Commercialization (CPDC), the sole supplier of Cellectar’s drug CLR 131.

  • MarketWatch2 months ago

    Cellectar stock surges 15% premarket after FDA fast tracks treatment for rare childhood cancer

    Cellectar Biosciences Inc. said Monday it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for a treatment for a rare kind of cancer in children called osteosarcoma. The treatment, CLR 131, is the company's lead Phospholipid Drug Conjugate(TM) (PDC) product candidate, which delivers radiation directly to cells. "CLR 131 has demonstrated promise as an anticancer agent in preclinical and clinical settings, and we are working now to establish its impact on various rare and deadly pediatric cancers," said John Friend, M.D., chief medical officer of Cellectar. The FDA assigns the RPDD to companies that are developing treatments for diseases that affect children from birth to 18 years old but have fewer than 200,000 patients. Osteosarcoma is caused by bone forming mesenchymal, or connective tissue, cells and is the most commonly diagnosed primary bone malignancy among children and adolescents, according to Cellectar. Shares were last up 15% premarket but are down 84.0% in 2018, while the S&P 500 has gained 8.7%.

  • GlobeNewswire2 months ago

    FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to CLR 131 for the treatment of osteosarcoma, a rare pediatric cancer. “CLR 131 has demonstrated promise as an anticancer agent in preclinical and clinical settings, and we are working now to establish its impact on various rare and deadly pediatric cancers,” said John Friend, M.D., chief medical officer of Cellectar.

  • GlobeNewswire3 months ago

    Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

    MADISON, Wis., Aug. 29, 2018-- Cellectar Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, ...

  • Benzinga3 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! TAL Education Group (ADR) (NYSE: TAL ) stock was trading ...

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: Cara Therapeutics and Cellectar Biosciences

    NEW YORK, NY / ACCESSWIRE / July 18, 2018 / U.S. stocks closed up on Tuesday, as the Federal Reserve announced that it would be flexible in the face of changing conditions and will not move too quickly ...

  • Benzinga4 months ago

    Cellectar Shares Climb After Strong Trial Response For Rare Blood Cancer Drug

    Cellectar Biosciences Inc (NASDAQ: CLRB ) shares are pushing northward on over five times their average volume after the company reported positive results from an ongoing midstage trial. Cellectar shares ...